Contenting Logo

News

Entertainment

Science & Technology

Sport

Business & Money

Life

Culture & Art

Hobbies

Sites
Lists
#tags
  1. home
    2. ›
  2. #tags
    3. ›
  3. Rial

Discover Latest #Rial News, Articles and Videos with Contenting

The following are news articles, blog posts, and videos related to Rial. You can explore them further for more information on the currency, its value, and its role in the global economy. News 1. Iran's Currency Reaches Record Low Against US Dollar In August 2018, Iran's currency, the rial, hit an all-time low against the US dollar. On August 8th, one US dollar was worth about 110,000 rials, making it more difficult for Iranian citizens to purchase goods and services. The drop in the value of the rial has been attributed to the upcoming sanctions from the US, as well as the country's economic mismanagement. 2. Iran Introduces New Currency In April 2019, the Iranian government announced that it would be introducing a new currency, the toman. The toman is equal to 10,000 rials, and was intended to reduce confusion and make transactions easier. The move was also seen as an attempt to boost the value of the rial, although it remains to be seen if this measure will be successful. Blog Posts 1. The Impact of US Sanctions on the Iranian Rial In this

ForexTV

23.01.2025

Q3 update for the three months ended 31 October 2024 - ForexTV

ICG Enterprise Trust plc23 January 2025Q3 update for the three months ended 31 October 2024           Highlights NAV per Share of 1,997p (31 July 2024: 1,946p)NAV per Share Total Return of 3.0% in Q3; long-term compounding returns of 13.8% annualised over last 5 yearsContinuing to invest through cycle: one new fund Commitment (£7.5m), Total New Investment of £35.2m and Total Proceeds of £34.4m (including 12 Full Exits at weighted average Uplift to Carrying Value of 18%)Evolving our medium-term target portfolio composition towards more secondary and direct investmentsTo date our shareholder-focused approach to capital allocation has delivered: Dividend per share increases at an annualised rate of 9% over last 5 years1 through our progressive dividend policy; and£50m of buybacks since October 20222 (£32m long-term, £18m opportunistic), adding 2.3% (47p) to NAV per Share and reducing share count by a market-leading3 6% Q3 dividend per share of 8.5p (Q3 FY24: 8.0p), Board intends to pay total dividends of at least 35p per share for FY25 (FY24: 33p). Opportunistic share buyback renewed for FY26 of up to £25m to run alongside long-term buybackBalance sheet flexibility strengthened post period-end through an increase in credit facility size from €240m to €300m 1 FY20 to FY25, including intended total dividends for year ended FY25 of at least 35p2 October 2022 being the start date for the long-term programme. Opportunistic programme started in May 2024. Both to 14 January 20253 Source: Deutsche Numis research, 'Opportunities abound in listed PE', data from Dec 2022 to Dec 2024 (excludes tender offers)   PERFORMANCE OVERVIEW       Annualised Performance to 31 October 20243 months1 year3 years5 years10 years Portfolio Return on a Local Currency Basis3.1%8.8%9.1%16.0%15.3% NAV per Share Total Return3.0%3.6%8.8%13.8%13.5% Share Price Total Return(7.5)%16.1%2.2%8.5%10.8% FTSE All-Share Index Total Return(2.5)%16.3%6.2%5.7%6.2%  Portfolio activity overview for Q3 FY25PrimaryDirectSecondaryTotalICG-managed Portfolio Return on a Local Currency Basis2.8%3.6%3.2%3.1%3.8% Portfolio Return in Sterling2.8%3.5%3.1%3.0%3.4% New Investments£27m£5m£4m£35m£4m Total Proceeds£25m£3m£6m£34m£4m New Fund Commitments£7m£—m£—m£7m£—m Closing Portfolio value£761m£461m£224m£1,445m£443m % Total Portfolio53%32%15%100%31% ENQUIRIES Institutional investors and analysts:         Martin Li, Shareholder Relations                        +44 (0) 20 3545 1816Nathan Brown, Deutsche Numis                        +44 (0) 20 7260 1426David Harris, Cadarn Capital                             +44 (0) 20 7019 9042 Media:                                        Clare Glynn, Corporate Communications, ICG        +44 (0) 20 3545 1395 To receive regular updates and insights from our Portfolio Managers, sign up to our newsletter here or visit our website at www.icg-enterprise.co.uk COMPANY TIMETABLE A presentation for investors and analysts will be held at 15:30 GMT today. A link for the presentation can be found on the Results & Reports page of the Company website. A recording of the presentation will be made available on the Company website after the event.  FY25 Third Interim DividendEx-dividend date13 February 2025Record date14 February 2025Dividend payment date28 February 2025 ABOUT ICG ENTERPRISE TRUST ICG Enterprise Trust is a leading listed private equity investor focused on creating long-term compounding growth by delivering consistently strong returns through selectively investing in profitable, cash-generative private companies, primarily in Europe and the US. We invest in companies directly as well as through funds managed by Intermediate Capital Group plc ("ICG") and other leading managers who focus on creating long-term value and building sustainable growth through active management and strategic change. ICG Alternative Investment Limited, a regulated subsidiary of ICG, acts as the Manager of the Company. NOTESIncluded in this document are Alternative Performance Measures (“APMs”). APMs have been used if considered by the Board and the Manager to be the most relevant basis for shareholders in assessing the overall performance of the Company, and for comparing the performance of the Company to its peers and its previously reported results. All performance figures are stated on a Total Return basis (i.e. including the effect of re-invested dividends). DISCLAIMER The information contained herein and on the pages that follow does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for, any securities in any jurisdiction where such an offer or solicitation is unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on ICG Enterprise Trust PLC (the "Company") or its affiliates or agents. Equity securities in the Company have not been and will not be registered under the applicable securities laws of the United States, Australia, Canada, Japan or South Africa (each an “Excluded Jurisdiction”). The equity securities in the Company referred to herein and on the pages that follow may not be offered or sold within an Excluded Jurisdiction, or to any U.S. person ("U.S. Person") as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or to any national, resident or citizen of an Excluded Jurisdiction. The information on the pages that follow may contain forward looking statements. Any statement other than a statement of historical fact is a forward looking statement. Actual results may differ materially from those expressed or implied by any forward looking statement. The Company does not undertake any obligation to update or revise any forward looking statements. You should not place undue reliance on any forward looking statement, which speaks only as of the date of its issuance. MANAGER’S REVIEW Our investment strategy Within developed markets, we focus on investing in buyouts of profitable, cash-generative businesses that exhibit defensive growth characteristics, which we believe will support strong and resilient compounding returns across economic cycles. We take an active approach to portfolio construction, with a flexible mandate that enables us to deploy capital in Primary, Secondary and Direct investments. Geographically we focus on the developed markets of North America and Europe which have deep and mature private equity markets supported by a robust corporate governance ecosystem. Investments managed by ICG accounted for 31% of the Portfolio.  Medium-term targetFive-year averageQ3 FY251. Target Portfolio composition 1   Investment category   Primary~40-50%58%53%Direct~30-35%29%32%Secondary~25-30%14%15%Geography   North America~50%42%44%Europe (inc. UK)~50%50%49%Other—7%7%    2. Balance sheet   Net cash/(net debt)2~0%~0%(7)%1 As percentage of Portfolio; 2 Net cash/(net debt) as a percentage of NAV Performance overview At 31 October 2024, the Portfolio was valued at £1,445m. The Portfolio Return on a Local Currency Basis for the quarter was 3.1% and in Sterling terms the Portfolio value grew by 3.0%ICG Enterprise Trust generated a NAV per Share Total Return of 3.0% during the quarter, ending the period with a NAV per Share of 1,997pOver the last five years ICG Enterprise Trust has generated an annualised NAV per Share Total Return of 13.8% Movement in the Portfolio£m3 months to31 October 2024Opening Portfolio1£1,402mTotal New Investments£35mTotal Proceeds£(34)mPortfolio net cashflow£1mValuation movement2£44mCurrency movement£(1)mClosing Portfolio£1,445m 1 Refer to the Glossary2 91.8% of the Portfolio is valued using 30 September 2024 (or later) valuations. NAV per Share Total Return3 months to 31 October 2024% Portfolio growth (local currency)3.1 Portfolio growth (Sterling)3.0%Impact of (net cash)/net debt0.2%Expenses and other income(0.4)%Co-investment Incentive Scheme Accrual(0.3)%Impact of dividend reinvestment0.1%Impact of share buybacks0.3%NAV per Share Total Return3.0% Quoted company exposure We do not actively invest in publicly quoted companies but gain listed investment exposure when IPOs are used as a route to exit an investment. In these cases, exit timing typically lies with the manager with whom we have investedAt 31 October 2024, ICG Enterprise Trust’s exposure to quoted companies was valued at £54m (31 July 2024: £60m), equivalent to 3.7% of the Portfolio value (31 July 2024: 4.3%). There was one quoted investment that individually accounted for 0.5% or more of the Portfolio value: CompanyTicker31 October 2024% of Portfolio valueChewyCHWY-US1.4%Other companies 2.3%Total 3.7% Realisation activity Realisation Proceeds of £34.4m during the quarter12 Full Exits completed during the quarter, at a weighted average Uplift to Carrying Value of 17.9% and a 4.0x Multiple to Cost New investment activity Total New Investments of £35.2m during the quarter, of which 12.2% (£4.3m) were alongside ICGThe split of Total New Investments by category was as follows: Investment CategoryCost (£m)% of New InvestmentsPrimary£27m76%Direct£5m14%Secondary£4m10%Total£35m100% Commitments One new fund Commitment totalling £7.5m during the quarter: FundManagerCommitment during the period  Local currency£mValeas Capital Partners IValeas$10.0m£7.5m At 31 October 2024, ICG Enterprise Trust had Total Undrawn Commitments of £430m to funds in their investment period and a further £130m to funds outside their investment period Balance sheet and liquidity Total available liquidity at 31 October 2024 was £107m (31 July 2024: £126m)On 23 December 2024, we announced an increase to the size of the revolving credit facility from €240m to €300m. Pro forma for this increase, ICGT would have had total available liquidity of £158m  £mCash at 31 July 202417Total Proceeds34New investments(35)Debt drawn down10Shareholder returns(12)Management fees(4)FX and other expenses(4)Cash at 31 October 20246Available undrawn debt facilities101Total available liquidity107Total available liquidity (pro-forma for increase in credit facility post period-end)158 The cash balance was £6m (31 July 2024: £17m) and drawn debt was £101m (31 July 2024: £93m). As a result, we had net debt of £95m (31 July 2024: £76m)At 31 October 2024 the Portfolio represented 111% of net assets (31 July 2024: 110%)  £m% of net assetsPortfolio1,445111%Cash6—%Drawn debt(101)(8)%Co-investment Incentive Scheme Accrual(47)(4)%Other net current liabilities(6)—%Net assets1,297100% Dividend and share buyback Third quarter dividend of 8.5p per share (Q3 FY24: 8p). The Board intends to pay total dividends of at least 35p per share for FY25 (FY24: 33p)The following purchases have been made under the Company's share buyback programmes:  Long-termOpportunisticTotal Q3 FY25Since inception1Q3 FY25Since inception2Q3 FY25Since inceptionNumber of shares purchased270,0002,689,688218,0001,492,175488,0004,181,863% of opening shares since buyback started     6.1%Capital returned to shareholders£3.3m£31.7m£2.6m£18.3m£5.9m£50.0mNumber of days shares have been acquired2117621123187Weighted average discount to last reported NAV35.9%38.4%37.7%36.2%36.7%37.6%NAV per Share accretion (p)    5p47pNAV per Share accretion (% of NAV)    0.3%2.3% 1 Since October 2022 (which was when the long-term share buyback programme was launched) up to and including 10 January 20252 Since May 2024 (which was when the opportunistic buyback programme was launched) up to and including 10 January 2025Note: aggregate consideration excludes commission, PTM and SDRT The Board is renewing the opportunistic share buyback programme for FY26 of up to £25m (FY25: up to £25m), with the same objectives as the FY25 programme. This will run alongside the long-term buyback programme and the progressive dividend policy Activity since the period end Notable activity between 1 November 2024 and 31 December 2024 has included: New investments of £23mRealisation Proceeds of £29m Our balance sheet flexibility was enhanced with an increase to the size of the revolving credit facility from €240m to €300m (see announcement here). ICG Private Equity Fund Investments Team22 January 2025

ForexTV

23.01.2025

European Shares Seen Lower; Central Bank Decisions And Trump's Tariff Plans In Focus - ForexTV

European stocks are anticipated to open predominantly lower on Thursday as investors seek further clarity regarding U.S. President Donald Trump's policy agenda.Asian markets displayed mixed trends, with upticks observed in the Chinese and Hong Kong markets. This followed the announcement of medium- and long-term investment plans by several Chinese government departments aimed at bolstering the country's struggling stock market.China has unveiled a strategic initiative to channel hundreds of billions of yuan annually from state-owned insurance companies into the stock market. This move is intended to enhance investor confidence and revitalize the market.The US dollar strengthened in anticipation of a series of central bank decisions expected in the coming week. Concurrently, gold edged down from a near three-month high, whereas oil prices decreased following industry reports indicating the first increase in U.S. crude stockpiles since mid-November.The yen remained relatively stable amid expectations that the Bank of Japan will raise interest rates at the conclusion of its two-day policy meeting on Friday.In terms of economic data releases, attention later in the day may turn to Eurozone consumer confidence survey results, alongside U.S. data on initial jobless claims and the Kansas City Fed manufacturing index.The U.S. stock market experienced gains overnight, propelling Wall Street toward record highs. This surge was supported by strong quarterly results from Netflix, optimism surrounding potential Federal Reserve rate cuts, and President Trump's new initiative focusing on artificial intelligence.The Dow Jones Industrial Average increased by 0.3%, the S&P 500 rose by 0.6%, and the technology-centric Nasdaq Composite advanced by 1.3%.On Wednesday, European stocks broadly rose, with sentiment bolstered by expectations of rate cuts from both the Federal Reserve and the European Central Bank, which countered concerns over Trump's tariff threats.The pan-European STOXX 600 index increased by 0.4%, reaching a nearly four-month high. Germany's DAX index climbed 1% to close at an all-time high, buoyed by Adidas’s strong holiday quarter performance. France's CAC 40 index jumped 0.9%, while the U.K.'s FTSE 100 ended slightly lower.The material has been provided by InstaForex Company - www.instaforex.com

ForexTV

23.01.2025

Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer - ForexTV

Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre for Drug Development to run the trial at sites in UK, and others across EuropeThe Norwegian Cancer Society to provide co-funding to support the trial LONDON, UK, and BERGEN and OSLO, Norway, 23 January 2025 – Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC). This rare and aggressive cancer, which affects the adrenal glands, has limited treatment options and an urgent need for new therapies. CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer cells, triggering a systemic immune response, while simultaneously inhibiting the Wnt/β-catenin signalling pathway, a key driver of immunotherapy resistance in cancers such as ACC. CY-101’s development builds on compelling data from Cytovation’s Phase 1 CICILIA trial, which demonstrated encouraging outcomes in patients with solid tumours. Notably, two ACC patients had clear clinical benefit, with one achieving 18 months of progression-free survival and continuing treatment on a named-patient basis. These results highlight CY-101’s potential to address the specific mechanisms of ACC. A collaborative approach Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will sponsor, design and deliver the Phase 2 trial and Cytovation will be responsible for providing CY-101 for the clinical trial. Cancer Research Horizons, Cancer Research UK’s innovation arm, will manage the commercial relationship between the three parties.  The Norwegian Cancer Society’s support provides access to the additional resources, patients and sites required for trials in rare diseases. Due to the rarity of ACC, the clinical trial will run across multiple sites in the UK and Europe, to ensure robust patient recruitment. Lars Erwig, Director of the Centre for Drug Development, Cancer Research UK, said: “This collaboration represents a critical step toward addressing the needs of ACC patients who currently have very few treatment options. Cytovation has made impressive progress with CY-101 so far and we are excited to build on our existing partnership with the Norwegian Cancer Society to take its development further.” Lars Prestegarden, CEO, Cytovation, said: “We are very excited about this partnership, proud to follow in the footsteps of groundbreaking agents that Cancer Research UK has contributed to developing, and honoured by the Norwegian Cancer Society’s support. We believe CY-101 has the potential to be transformational for the treatment of ACC and other cancer types and are eager to bring this innovation to patients.” Ingrid Stenstadvold Ross, CEO of the Norwegian Cancer Society, said: “The partnership with Cancer Research UK’s Centre for Drug Development marks a milestone for the Norwegian Cancer Society, enabling us to advance the development of groundbreaking cancer treatments. We are thrilled that our first joint project is a Norwegian innovation, focused on patients with a rare cancer and a substantial unmet need. Together with Cancer Research UK’s Centre for Drug Development and Cytovation, we are bringing new hope to patients while highlighting Norwegian research on the international stage.” ENDS About Cancer Research UK’s Centre for Drug Development   Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years, taking over 160 potential new anti-cancer agents into clinical trials in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other drugs are in late development Phase 3 trials. Thirteen agents remain in active development with the potential to reach the market. It currently has a portfolio of 16 projects in preclinical development, Phase 1 or early Phase 2 clinical trials. www.cruk.org.uk/cdd   About Cytovation Cytovation ASA is a clinical stage biotech company focused on the development of CY-101, a first-in-class bifunctional immunotherapy. CY-101 has a unique dual mechanism of action, specifically eliminating cancer cells by targeting the cell membrane and releasing neo-antigens, and by inhibiting the Wnt/β-catenin oncogenic pathway to restrict tumour growth and reverse immune exclusion associated with β-catenin expression. Dysregulation of this pathway has been associated with several different cancer types including colon, liver, uterine, lung and ovarian cancer, among others. This dual mode of action induces a systemic, tumour-specific immune response. For more information, please visit www.cytovation.com. About the Norwegian Cancer Society The Norwegian Cancer Society (NCS) is one of the largest organisations in Norway. It represents the voices of those affected by cancer. We have 128,000 members, 27,000 volunteers and 190 employees. All are dedicated to promoting cancer cause. NCS works continuously to improve society’s attitude to the prevention and treatment of cancer. We fight cancer locally, nationally and globally. Through research and preventive measures, information, support, advice and lobbying. The Norwegian Cancer Society’s purpose is to work to prevent and fight cancer. And to improve quality of life for patients and their families. Our vision is a life without cancer. For further information about the work of NCS, please visit www.kreftforeningen.no. Contacts Cancer Research UK Tim Bodicoat Content Manager Cancer Research UK tim.bodicoat@cancer.org.uk Cytovation ASA Federico GregoCOO/CFOCytovation ASAcontact@cytovation.com Frazer Hall/Mark Swallow MEDiSTRAVA cytovation@medistrava.com Norwegian Cancer Society Ola Henmo Norwegian Cancer Society ola.henmo@kreftforeningen.no

ForexTV

23.01.2025

Nxera Pharma Webinar Presentation for FY2024 Financial Results - ForexTV

Tokyo, Japan and Cambridge, UK, 23 January 2025 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2024 on Friday, 14 February 2025. The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, President of Nxera Pharma UK and Head of UK R&D and Makoto Sugita, President of Nxera Pharma Japan and Chief Medical Officer, at 5:00 pm JST (8:00 am GMT) on Friday, 14 February 2025. The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&A session. Please click here to pre-register, which will provide a link to access the webinar. Presentation slides will be made available by 4:30 pm JST (7:30 am GMT) on 14 February 2025 through the investor section of the Company’s Home Page here. – ENDS – About Nxera PharmaNxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsKentaro Tahara, VP Investor Relations and Corporate StrategyShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contenting Logo
About UsPrivacy PolicyTerms Of UseContact